



Zorvolex® (diclofenac) – First-time authorized brand alternative

- On September 16, 2020, TriVue Pharmaceuticals launched an authorized brand alternative of Iroko's [Zorvolex \(diclofenac\)](#) capsules.
- Zorvolex is approved for the management of mild to moderate acute pain and osteoarthritis (OA) pain.
- Oral prescription diclofenac is available generically as a [potassium salt tablet](#), [potassium salt oral solution](#), [combination sodium salt and misoprostol delayed-release tablet](#), [sodium salt delayed-release tablet](#), [sodium salt extended-release tablet](#), and brand potassium salt capsule ([Zipsor®](#)),
 - Diclofenac potassium is approved for treatment of primary dysmenorrhea, for relief of mild to moderate pain, for relief of the signs and symptoms of OA and rheumatoid arthritis (RA).
 - Diclofenac potassium for oral solution is indicated for the acute treatment of migraine attacks with or without aura in adults (18 years of age or older).
 - Combination diclofenac sodium and misoprostol is indicated for the treatment of the signs and symptoms of OA or RA in patients at high risk of developing nonsteroidal anti-inflammatory drug-induced gastric and duodenal ulcers and their complications.
 - Diclofenac sodium delayed-release tablet is indicated for relief of the signs and symptoms of OA and RA, and for the acute or long-term use in the relief of the signs and symptoms of ankylosing spondylitis.
 - Diclofenac sodium extended-release tablet is indicated for relief of the signs and symptoms of OA and RA.
 - Zipsor is indicated for relief of mild to moderate acute pain in adults (18 years of age or older).
- Zorvolex carries a boxed warning for risk of serious cardiovascular and gastrointestinal events.



OptumRx® specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum® company — a leading provider of integrated health services. Learn more at [optum.com](#).

All Optum® trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews® is published by the OptumRx Clinical Services Department.

©2020 Optum, Inc. All rights reserved.